RE: Quiet board so far this morning and we are +16.25% UP!20 Nov 2020 10:05
I am pretty sure I understand the underpinnings and implications of the technology (due to my day job). Some of it is really straightforward. Here is a paragraph I wrote after the Stonechecker trials in 2017: "Clinicians participating in the tests were unexpectedly enthusiastic about StoneChecker's reporting of the basic stone parameters: position in the body, volume, and shape. This automatically-provided, straightforward information allows the clinician to align the lithotripsy equipment more accurately, making the treatment more effective and the clinician's job much easier. These outputs from StoneChecker are much more straightforward than the composite score which the software was designed to produce, and are consequently a much easier sell. It seems likely that the software will be quickly adopted by a majority of kidney stone treatment providers."
I really hate resorting to conspiracy theories, but the straight line in share price vs time looks extremely dodgy to me, I don't think it's likely that market forces would move the price in such a steady way over the last 5 days.
Personally it is interesting to read a variety of opinions.
I think it was me that frickd was having a pop at, though I didn't say hundreds of millions based on Stonechecker alone. What I wrote was: "Back in 2017 I calculated a plausible market cap of £150M based on successful execution of the Stonechecker (kidney stone imaging) rollout alone:
"The cost of a single lithotripsy treatment is around £750 in India or the Philipines. If we adopt this as an average global cost, assume a potential population with access to treatment of 3 billion people, and assume that StoneChecker is licensed for use on a single patient by StoneChecker Software Ltd for 0.1% of the cost of a single lithotripsy treatment, this indicates an annual revenue stream of £18M. Software companies have relatively fixed costs, so the overwhelming majority of this revenue should become net income. If we assume a price-earnings ratio of 10, this implies a market cap around £150M once StoneChecker is widely adopted."
I think if frickd disagrees with my conclusion frickd should point out which part of the reasoning above is wrong.
I am pretty sure hasiba's buy was real as I saw it on the reported trades.
I think £150M is undervaluing the IP by a considerable margin - factor of 3 or 4 at least. I think Stonechecker alone, if successfully deployed globally commands a market cap of £150M. I posted my reasoning supporting this a couple of times already recently.
why gad-free will be adopted rapidly in the US at least15 Nov 2020 17:51
"Gadolinium-based contrast agents (GBCAs) are used over 10 million times worldwide each year in magnetic resonance imaging (MRI) scans to diagnose and characterize disease states affecting the central nervous system ...
In 2006 an association was established between GBCAs and a rare but devastating, and sometimes fatal, fibrosing disorder termed nephrogenic systemic fibrosis (NSF) in patients with impaired kidney function. ...
Deposition of Gd in the brain and other organs, e.g. bone, has been observed with all GBCAs regardless of kidney function ... The FDA assigned a new class warning to all GBCAs advising physicians to carefully consider the retention characteristics of a GBCA before prescribing contrast enhanced examinations. ...
All intravenous contrast agents approved for use and that are commercially available contain Gd.
@JAdam well that's an interpretation, but as a long-term holder I recognise that he has built the value in my multi-bagged holding. If one was going to object to the CLN, the time to do it was when they were issued. And the sales are to stay below 30% of the company. We are not daft!